USPTO serial 79368062
ZYTONOVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 14, 2024
- Examiner
- MARTIN, JENNIFER MCGARRY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ZYTONOVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Laurence P. Colton
Laurence P. Colton SMITH TEMPEL BLAHA LLC1600 Parkwood Circle SE, Suite 620Atlanta, GA 30339UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; biochemicals, namely, polynucleotides, oligonucleotides, peptides, proteins, enzymes, and antibodies for in vitro scientific and research purposes; chemicals and biochemicals, namely, nucleic acids and antibodies for use in the detection of genetic alterations, other than for medical or veterinary purposes; nucleic acids and antibodies for laboratory use; chemicals for use in industry and science, namely, dna probes, rna probes and oligonucleotide probes being biochemical substances, antibodies, enzymes, and oligonucleotides for carrying out molecular biological processes; mixtures of chemical reagents in kit form, other than for medical or veterinary purposes, namely, kits for scientific purposes consisting primarily of chemical reagents | ACTIVE | — |
| 005 | Medical preparations, namely, medical diagnostic reagents for diagnosis of genetic disorders; medical preparations for diagnostics, namely, medical diagnostic reagents for diagnosis of genetic aberrations in tumors; medical preparations for in vitro diagnostics, namely, test kits containing antibodies, probes, enzymes, buffers and reagents for diagnosis of genetic disorders including genetic aberrations in tumors; nucleic acids sequences, peptide sequences, and chemical reagents for medical and veterinary purposes; biological and chemical preparations, namely, dna, rna and oligonucleotide probes composed of biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for medical and veterinary diagnostic purposes; biological and chemical preparations for medical and veterinary purposes, namely, dna probes, rna probes and oligonucleotide probes being polynucleotides, biochemical substances, oligonucleotides, proteins and enzymes and antibodies for diagnosis of genetic disorders including genetic aberrations in tumors; diagnostic biomarker reagents for medical purposes | ACTIVE | — |
| 009 | Research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; analysis apparatus, namely, research laboratory analyzers, for measuring, testing and examining tissue, cells and biomolecules including dna, rna and proteins | ACTIVE | — |
| 010 | Medical analytical apparatus for medical purposes, namely, medical diagnostic instruments for the analysis of dna, rna and proteins; automatic analyzers for medical diagnosis, namely, medical diagnostic instruments for the analysis of body fluids and tissues; genetic testing apparatus for medical purposes | ACTIVE | — |
| 035 | Business management consultancy and advisory services; operation of businesses for others, namely biotechnological and medical companies; running of a holding company performed for third parties, namely business management, business administration, and providing office functions; holding company services performed for third parties, namely, development of marketing strategy, business management and business management consultation; business management and organization consultation; advisory services relating to business management; business administration; providing office functions; business development services, namely, planning and monitoring of business developments and organizational services for business purposes | ACTIVE | — |
| 042 | Science and technology services, namely, research and design in the field of genetic analyses including analyses of genetic alterations in tumors; medical laboratory services; medical research laboratory services; development of pharmaceutical preparations and medicines; clinical research, namely conducting clinical trials for others; research relating to biotechnology; scientific consultancy services relating to hazardous materials management; biological analysis, biochemical analysis, chemical analysis, scientific analysis, namely, dna, rna, and protein analysis services for scientific research purposes; scientific research in the field of genetics and genetic engineering | ACTIVE | — |
| 044 | Medical services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; in-vitro analysis for medical and pharmaceutical use, namely, medical services in the field of genetic disorders including genetic aberrations in tumors; medical services using the knowledge in the field of pathology, genetic science, human genetics, molecular pathologies, molecular biology, microbiology, biotechnology and laboratory medicine; medical services by means of histology, cytology, immunohistology, immunohistochemistry, in situ hybridization, pcr (polymerase chain reaction), ngs (next generation sequencing), microarray hybridization (genetic chip or biochip hybridization), flow cytometry and isolation of biomolecules including DNA, RNA and proteins; medical counseling; pharmaceutical compounding services; pharmaceutical advice; medical and healthcare services relating to dna, genetics and genetic testing; medical pathology services, namely pathology diagnostic services; genetic testing for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ZytoVision GmbH
- Other trademarks owned by ZytoVision GmbH
- Other trademarks owned by ZytoVision GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ZYTONOVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 6, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 30, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 9, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 8, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 14, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 14, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 14, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 27, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 27, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 7, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 7, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 23, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 22, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 22, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 13, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 13, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 13, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 10, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 25, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 25, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 7, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 6, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 20, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |